News Posts List

Cambium Enrolls First Patient in Phase I/II Study to Evaluate Platelet Lysate Biologic for Graft-vs.-Host Disease Dry Eye


Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today first patient enrollment for its Elate Ocular topical fibrinogen-depleted human platelet lysate biologic in a randomized, multicenter, double-masked placebo-controlled parallel Phase I/II study. The study is designed to determine safety and exploratory efficacy in patients with dry eye secondary to graft-versus-host disease. The core study involves a minimum of 60 patients at up to five U.S. eye centers. Including two sub-studies, a maximum of 108 patients may be enrolled in the overall study.

“To our knowledge, our study is the first to evaluate a standardized, cGMP processed, allogeneic (donor sourced) versus autologous (patient sourced), enriched platelet-rich-plasma lysate serum drop in a U.S. IND sanctioned dry eye clinical trial,” said Terence Walts, President & CEO of Cambium. “The industry already recognizes autologous and PRP serum as generally proven therapies to treat the symptoms of not only dry eye but numerous additional corneal diseases and conditions. To date, however, their use has been largely relegated to end stage, failed meds status for inherent reasons unrelated to efficacy. Cambium believes, following approvals--its Elate Ocular product has potential as a main stage, first line therapy for many corneal diseases and conditions including GvHD dry eye,” said Walts.

About Cambium Medical Technologies LLC:

Founded in 2013 by four distinguished physician/scientists at Emory University, Atlanta, Georgia (USA)—Cambium is focused on the development of regenerative therapies through the use of novel processed human platelets. Cambium’s Mission: To improve patients’ quality of life—from within. The Company’sfirst FDA-approved therapy is targeted to be Elate OcularTM, a topical eye drop for dry eye syndrome (keratoconjunctivis sicca or KCS). Elate OcularTM utilizes AurarixTM, Cambium’s novel processedenriched platelets depleted of fibrinogen, the clotting agent in platelets. Cambium’s Aurarix technology is currently sold worldwide as UltraGROTM-Advanced and UltraGROTM -PURE in the stem cell growth

supplement market by Cambium’s strategic partner AventaCell Biomedical Corp., Ltd, a subsidiary of Zheng Yang Biomedical Technology Co., Ltd—both headquartered in Taipei, Taiwan with manufacturing facilities in Atlanta, GA.

For more information about Cambium, contact David Doolittle at +1 404-337-5990 or e-mail David at, or go to To learn more about AventaCell and their line of UltraGROTM stem cell growth supplements, contact William D. Milligan at or visit